AP2015008801A0 - Methods for treating crohn's disease using an anti-il23 antibody - Google Patents

Methods for treating crohn's disease using an anti-il23 antibody

Info

Publication number
AP2015008801A0
AP2015008801A0 AP2015008801A AP2015008801A AP2015008801A0 AP 2015008801 A0 AP2015008801 A0 AP 2015008801A0 AP 2015008801 A AP2015008801 A AP 2015008801A AP 2015008801 A AP2015008801 A AP 2015008801A AP 2015008801 A0 AP2015008801 A0 AP 2015008801A0
Authority
AP
ARIPO
Prior art keywords
antibody
disease
methods
treating crohn
crohn
Prior art date
Application number
AP2015008801A
Other languages
English (en)
Inventor
Wayne Tsuji
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AP2015008801A0 publication Critical patent/AP2015008801A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
AP2015008801A 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody AP2015008801A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15
PCT/US2014/018308 WO2014143540A1 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Publications (1)

Publication Number Publication Date
AP2015008801A0 true AP2015008801A0 (en) 2015-10-31

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008801A AP2015008801A0 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Country Status (17)

Country Link
US (5) US20160031983A1 (es)
EP (2) EP2968486A1 (es)
JP (4) JP2016516686A (es)
KR (1) KR20150128859A (es)
CN (1) CN105307675A (es)
AP (1) AP2015008801A0 (es)
AU (1) AU2014228553B2 (es)
CA (1) CA2906384A1 (es)
CL (1) CL2015002724A1 (es)
EA (1) EA201591579A1 (es)
HK (1) HK1220605A1 (es)
IL (2) IL241343A0 (es)
NZ (1) NZ712294A (es)
PH (1) PH12015502133A1 (es)
SG (2) SG11201507483PA (es)
TN (1) TN2015000402A1 (es)
WO (1) WO2014143540A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (zh) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向IL-23A與TNF-α之化合物及其用途
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR103782A1 (es) * 2015-02-26 2017-05-31 Genentech Inc ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3436477A2 (en) * 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
EP3848390A1 (en) * 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
KR20210032441A (ko) * 2018-07-13 2021-03-24 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 브라지쿠맙을 이용한 궤양성 대장염의 치료
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
CN114641493A (zh) * 2019-08-21 2022-06-17 阿斯特捷利康合作创业有限责任公司 使用布雷库单抗治疗克罗恩病
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
EA013506B1 (ru) 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
US7807160B2 (en) 2005-08-31 2010-10-05 Schering Corporation Engineered anti-IL-23 antibodies
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
EP2064242A1 (en) * 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
RU2497545C2 (ru) * 2008-03-18 2013-11-10 Эбботт Лэборетриз Способ лечения псориаза (варианты)
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
EP2435480A1 (en) * 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
MX341309B (es) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
EP4137514A1 (en) * 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
CN103596978A (zh) * 2011-01-07 2014-02-19 阿布维公司 抗il-12/il-23抗体及其用途

Also Published As

Publication number Publication date
JP2016516686A (ja) 2016-06-09
AU2014228553B2 (en) 2019-01-24
SG11201507483PA (en) 2015-10-29
EP2968486A1 (en) 2016-01-20
AU2014228553A1 (en) 2015-10-08
US20160031983A1 (en) 2016-02-04
CN105307675A (zh) 2016-02-03
SG10201805015TA (en) 2018-07-30
EA201591579A1 (ru) 2016-01-29
CL2015002724A1 (es) 2016-03-28
CA2906384A1 (en) 2014-09-18
EP3693007A1 (en) 2020-08-12
PH12015502133A1 (en) 2016-01-25
JP2023012516A (ja) 2023-01-25
US20200017581A1 (en) 2020-01-16
US20170218062A1 (en) 2017-08-03
US20180327490A1 (en) 2018-11-15
JP2021107397A (ja) 2021-07-29
US20200283517A1 (en) 2020-09-10
TN2015000402A1 (fr) 2017-01-03
HK1220605A1 (zh) 2017-05-12
JP2020073470A (ja) 2020-05-14
KR20150128859A (ko) 2015-11-18
IL275092A (en) 2020-07-30
IL241343A0 (en) 2015-11-30
NZ712294A (en) 2020-04-24
WO2014143540A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
IL275092A (en) Methods for treating Crohn's disease using an anti-IL-23 antibody
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
TWI563003B (en) Human anti-il-33 neutralization monoclonal antibody
IL245196A0 (en) Antibodies against cd38 for the treatment of human cancers
HK1212710A1 (zh) 用於選擇針對 的抗體的方法
IL262804A (en) Antibodies to human pac1
ZA201504861B (en) Apparatus for improved disease detection
HK1215373A1 (zh) 用於治療代謝疾病的方法和裝置
IL244042A0 (en) A method for treating leiftic disease
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HK1217910A1 (zh) 骨用生物特異性試劑
EP3024482A4 (en) Methods for diagnosing and treating immune disease
PT2959903T (pt) Medicamento para tratar doença ocular
HK1219961A1 (zh) 人抗α型干擾素抗體
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
IL252904A0 (en) Methods and factors for treating diseases
GB201312226D0 (en) Improved antibodies
SI3016977T1 (sl) Humana protitelesa proti IL-32
EP2947462A4 (en) SAMPLE PROCESSING SYSTEM
GB201309509D0 (en) Diagnostic marker for crohn's disease
GB201302884D0 (en) Novel methods for diagnosis and therapy